Specifically, objective response rate (ORR) values of over 20% have been observed with HD IL2 monotherapy in immune-checkpoint inhibitor (ICI) failed melanoma and renal cell carcinoma (RCC) patients, comparable with historical response rates in ICI-naive patients (2, 3). The gene discussed is IL2; the disease is melanoma.